Misoprostol for Cervical Ripening Before Copper Intrauterine Device Removal
NCT ID: NCT03600064
Last Updated: 2020-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2019-07-01
2020-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The intrauterine device is usually removed by firmly grasping the threads at the external os; traction should be applied away from the cervix. If resistance is present, the removal should be stopped until it is determined why the intrauterine device is not moving. Some deeply embedded intrauterine device may need to be removed by hysteroscope \[4\].
In practice, many women, however, have an intolerable pain during intrauterine device removal and some of them requesting painkiller or even anesthesia to allow the physician to remove it. Cervical hardening and adhesions are the major factors making IUD removal difficult especially in post-menopausal women.
Insertion and removal of IUD in nulliparous women is possible but it may carry more pain, more difficulty than in parous women. We think that this problem is also present in women has no vagina delivery before. So, the intrauterine device removal actually has some difficulty or pain in the nulliparous women, women delivered by elective caesarian section or postmenopausal women.
Many medical agents for cervical ripening prior to the removal have been emerged like misoprostol. Misoprostol is commonly used for cervical ripening in the first and second trimester miscarriage and prior intrauterine devices insertion. The use of vaginal misoprostol before intrauterine device insertion in women who had never delivered vaginally before may increase the ease and success of insertion with pain felt during the procedure .
However and up to our knowledge; no studies had been reported the effect of misoprostol on removal pain in women delivered only by elective cesarean section.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Misoprostol Prior to Intrauterine Contraceptive Device Insertion
NCT02412033
Misoprostol Prior to Intrauterine Device Insertion
NCT04932382
Efficacy and Safety of Different Doses of Vaginal Misoprostol Prior to Intra Uterine Contraceptive Device Insertion
NCT04273984
Vaginal Misoprostol Before IUD Insertion in Women With Cesarean Scar
NCT03081442
Use of Misoprostol for Intrauterine Device (IUD) Insertion in Nulliparous Women
NCT01001897
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Misoprostol group
Misoprostol
the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (MisotacĀ®; Sigma Pharma, SAE, Egypt).
NO intervention
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Misoprostol
the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (MisotacĀ®; Sigma Pharma, SAE, Egypt).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Menstruating women
3. Nonpregnant women
4. Delivered before only by elective cesarean section
5. Women who did not receive any analgesics in the 24 h prior to Intrauterine device removal.
6. Using copper 380 A Intrauterine device for contraception only
7. Requesting Intrauterine device removal for returning of fertility
Exclusion Criteria
2. Ultrasonographic evidence of displaced Intrauterine device.
3. Women who will refuse to participate in the study.
4. Women who had any other type of Intrauterine device.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohammed Khairy Ali
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women Health Hospital - Assiut university
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIUD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.